The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
dow jones faces longest losing streak since 1970s amid economic concerns
Investors are concerned that Trump's potential trade tariffs could exacerbate inflation, as retail sales rose 0.7% in November. The Dow Jones is on track for its longest losing streak since the 1970s, while Nvidia faces challenges with thermal issues in its chips, impacting its stock. Tesla continues to rise, with analysts projecting a bullish outlook for 2025.
stock market retreats as nvidia falters and bitcoin hits new high
U.S. stock indexes pulled back, with the S&P 500 down 0.4% and Nvidia's stock falling 1.2%, marking its eighth loss in nine days. Despite this, the S&P 500 is up nearly 27% for the year, buoyed by strong economic resilience and expectations of favorable policies from President-elect Trump. Bitcoin briefly surpassed $108,000 before retreating to around $106,500.
UBS Maintains Neutral Rating on Pfizer with 31 Dollar Price Target
UBS has maintained a 'Neutral' rating for Pfizer, setting a price target of 31 US dollars. Analyst Trung Huynh noted that the pharmaceutical company's outlook for 2025 did not present any surprises in his initial reaction.
Pfizer Inc Sales Breakdown Highlights Dominance in Primary Care and Oncology
Pfizer Inc. is the leading pharmaceutical company globally, with sales categorized into primary care products (52.3%), specialty care products (25.6%), oncology (19.9%), and others (2.2%). Geographically, 46.3% of sales come from the United States, 19.9% from Europe, and 33.8% from other regions.
us stocks decline as investors await federal reserve interest rate decision
US stocks declined on Tuesday as investors grew cautious ahead of the Federal Reserve's interest rate decision, following strong retail sales data. The Dow Jones fell 231.55 points to 43,487.22, while the S&P 500 and Nasdaq Composite also experienced losses. Pfizer's stock rose 4.1% after projecting higher profits for 2025, contrasting with a dip in Nvidia shares by 3.5%.
Broadcom's stock continued to rally, while Nvidia faced further declines, entering correction territory. Advanced Micro Devices is projected to miss revenue targets, raising concerns, as the Dow is set for a down open after eight consecutive sessions of losses. Retail sales exceeded expectations, and the Federal Reserve is anticipated to cut interest rates again, with key inflation data due later this week.
stocks decline as dow extends losing streak ahead of fed decision
Stocks slipped as the Dow fell for the ninth consecutive day, its longest slump since 1978, ahead of the Federal Reserve's rate decision. Teva and Sanofi shares soared after positive drug trial results, while Amentum and EVgo faced declines due to concerns over future growth and investor sell-offs, respectively. Pfizer's shares rose after affirming its 2024 projections and providing a 2025 outlook in line with expectations.
sangamo shares soar after roche halts hemophilia a gene therapy program
Sangamo Therapeutics' shares surged by 36% following Roche's decision to discontinue its gene therapy program for hemophilia A, specifically the SPK-8011 therapy. This marks Sangamo's largest stock increase since October 28. The company is collaborating with Pfizer on a competing gene therapy, giroctocogene fitelparvovec, targeting the same condition.
sangamo shares rise sharply after roche halts hemophilia gene therapy program
Sangamo Therapeutics saw its shares soar by 36% after Roche announced the discontinuation of its gene therapy program for hemophilia A, specifically the SPK-8011 therapy. This decision, described as a "strategic decision," follows Roche's acquisition of Spark Therapeutics in 2019. Sangamo is collaborating with Pfizer on a competing gene therapy, giroctocogene fitelparvovec, targeting the same condition.
global bisoprolol fumarate market poised for significant growth through 2032
The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.